BCHE and myasthenia gravis: Of the remaining evaluable patients, 1 achieved MM‐1 (no functional limitation associated with MG but there is some mild weakness on exam and the patient has received some form of immunotherapy within the past 1 year) and one achieved MM‐3 (no functional limitation associated with MG but there is some mild weakness on exam and the patient has received symptomatic therapy with a cholinesterase inhibitor and some form of immunotherapy within the last 1 year).24